Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1996 1
1999 2
2003 1
2008 1
2015 3
2016 2
2018 1
2019 1
2020 4
2021 2
2022 3
2023 4
2024 2
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Results by year

Filters applied: . Clear all
Page 1
[Renal Damage and Obesity: a Silent Pairing].
Nazzaro P, Amatuzio A, Baranello S, Corvinelli M, Di Cienzo G, Principe F, Trucillo P, Buondonno A, Vitagliano C, De Stefano F. Nazzaro P, et al. Among authors: vitagliano c. G Ital Nefrol. 2023 Jun 29;40(3):2023-vol3. G Ital Nefrol. 2023. PMID: 37427903 Review. Italian.
Rationale and Design of PURE: A Randomized Controlled Trial to Evaluate Peritoneal Ultrafiltration with PolyCore™ in Refractory Congestive Heart Failure.
Gronda E, Gallieni M, Pacileo G, Capasso G, Wei LJ, Trepiccione F, Heidempergher M, Bonomini M, Zimarino M, Divino-Filho JC, Di Liberato L, Caracciolo MM, Masola V, Prosdocimi T, Iacobelli M, Vitagliano C, Arduini A. Gronda E, et al. Among authors: vitagliano c. Kidney Blood Press Res. 2024;49(1):852-862. doi: 10.1159/000541127. Epub 2024 Aug 28. Kidney Blood Press Res. 2024. PMID: 39197425 Free article.
Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy.
Costantini S, Madonna G, Capone M, Di Gennaro E, Bagnara P, Renza F, Mallardo D, Affatato R, Vitagliano C, Romanelli M, Tuffanelli M, Simeone E, Ciliberto G, Ascierto PA, Budillon A. Costantini S, et al. Among authors: vitagliano c. J Exp Clin Cancer Res. 2025 Apr 10;44(1):119. doi: 10.1186/s13046-025-03378-8. J Exp Clin Cancer Res. 2025. PMID: 40211360 Free PMC article.
Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3.
Rizzo R, Russo D, Kurokawa K, Sahu P, Lombardi B, Supino D, Zhukovsky MA, Vocat A, Pothukuchi P, Kunnathully V, Capolupo L, Boncompain G, Vitagliano C, Zito Marino F, Aquino G, Montariello D, Henklein P, Mandrich L, Botti G, Clausen H, Mandel U, Yamaji T, Hanada K, Budillon A, Perez F, Parashuraman S, Hannun YA, Nakano A, Corda D, D'Angelo G, Luini A. Rizzo R, et al. Among authors: vitagliano c. EMBO J. 2021 Apr 15;40(8):e107238. doi: 10.15252/embj.2020107238. Epub 2021 Mar 22. EMBO J. 2021. PMID: 33749896 Free PMC article.
Regorafenib monotherapy as second-line treatment of patients with RAS-mutant advanced colorectal cancer (STREAM): an academic, multicenter, single-arm, two-stage, phase II study.
Cardone C, De Stefano A, Rosati G, Cassata A, Silvestro L, Borrelli M, Di Gennaro E, Romano C, Nappi A, Zanaletti N, Foschini F, Casaretti R, Tatangelo F, Lastoria S, Raddi M, Bilancia D, Granata V, Setola S, Petrillo A, Vitagliano C, Gargiulo P, Arenare L, Febbraro A, Martinelli E, Ciardiello F, Delrio P, Budillon A, Piccirillo MC, Avallone A. Cardone C, et al. Among authors: vitagliano c. ESMO Open. 2023 Feb;8(1):100748. doi: 10.1016/j.esmoop.2022.100748. Epub 2023 Jan 3. ESMO Open. 2023. PMID: 36603521 Free PMC article. Clinical Trial.
Plasma metabolomics, lipidomics and cytokinomics profiling predict disease recurrence in metastatic colorectal cancer patients undergoing liver resection.
Costantini S, Di Gennaro E, Capone F, De Stefano A, Nasti G, Vitagliano C, Setola SV, Tatangelo F, Delrio P, Izzo F, Avallone A, Budillon A. Costantini S, et al. Among authors: vitagliano c. Front Oncol. 2023 Jan 11;12:1110104. doi: 10.3389/fonc.2022.1110104. eCollection 2022. Front Oncol. 2023. PMID: 36713567 Free PMC article.
Correction to: HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: vitagliano c. J Exp Clin Cancer Res. 2022 Apr 11;41(1):138. doi: 10.1186/s13046-022-02324-2. J Exp Clin Cancer Res. 2022. PMID: 35410264 Free PMC article. No abstract available.
HDAC class I inhibitor domatinostat sensitizes pancreatic cancer to chemotherapy by targeting cancer stem cell compartment via FOXM1 modulation.
Roca MS, Moccia T, Iannelli F, Testa C, Vitagliano C, Minopoli M, Camerlingo R, De Riso G, De Cecio R, Bruzzese F, Conte M, Altucci L, Di Gennaro E, Avallone A, Leone A, Budillon A. Roca MS, et al. Among authors: vitagliano c. J Exp Clin Cancer Res. 2022 Mar 3;41(1):83. doi: 10.1186/s13046-022-02295-4. J Exp Clin Cancer Res. 2022. PMID: 35241126 Free PMC article.
28 results